Search Results - "Audeh, M.W."

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis by Penson, R.T, Domchek, S.M, Kaufman, B, Audeh, M.W, Kaye, S.B, Molife, L.R, Mann, H, Robertson, J, Coleman, R.L

Get full text

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety by Matulonis, U.A., Penson, R.T., Domchek, S.M., Kaufman, B., Shapira-Frommer, R., Audeh, M.W., Kaye, S., Molife, L.R., Gelmon, K.A., Robertson, J.D., Mann, H., Ho, T.W., Coleman, R.L.

“…The PARP inhibitor olaparib (Lynparza™) demonstrates antitumor activity in women with relapsed ovarian cancer and a germline BRCA1/2 mutation (gBRCAm). Data…”
Get full text